Citius Pharmaceuticals Enters Material Definitive Agreement
Ticker: CTXR · Form: 8-K · Filed: Jun 12, 2025 · CIK: 1506251
Sentiment: neutral
Topics: material-definitive-agreement, filing
Related Tickers: CTRS
TL;DR
CTRS inks a big deal, filing shows. Details TBD.
AI Summary
Citius Pharmaceuticals, Inc. announced on June 9, 2025, the entry into a material definitive agreement. The company, incorporated in Nevada, filed an 8-K report detailing this event. Further specifics regarding the agreement, including parties involved and financial terms, are not detailed in the provided excerpt.
Why It Matters
This filing indicates a significant new contract or partnership for Citius Pharmaceuticals, which could impact its future operations and financial performance.
Risk Assessment
Risk Level: medium — The filing indicates a material definitive agreement, which is significant but lacks specific details about the nature or financial implications of the agreement.
Key Players & Entities
- Citius Pharmaceuticals, Inc. (company) — Registrant
- June 9, 2025 (date) — Date of earliest event reported
- Nevada (jurisdiction) — State of incorporation
- 11 Commerce Drive, 1st Floor, Cranford, NJ 07016 (address) — Principal executive offices
FAQ
What is the nature of the material definitive agreement entered into by Citius Pharmaceuticals?
The provided excerpt does not specify the nature of the material definitive agreement.
Who are the other parties involved in this material definitive agreement?
The excerpt does not name the other parties involved in the agreement.
What is the effective date of this material definitive agreement?
The earliest event reported is dated June 9, 2025.
What is Citius Pharmaceuticals' principal executive office address?
Citius Pharmaceuticals' principal executive office is located at 11 Commerce Drive, 1st Floor, Cranford, NJ 07016.
In which state is Citius Pharmaceuticals incorporated?
Citius Pharmaceuticals, Inc. is incorporated in Nevada.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 12, 2025 regarding Citius Pharmaceuticals, Inc. (CTXR).